In this month's issue
Roche has unveiled plans this morning to cut costs in response to pricing pressures and recent pipeline failures World News
UK drug giant GlaxoSmithKline has confirmed that prescribing information regarding its cervical cancer jab Cervarix has been updated to show that it offers broader protection against the disease.
UK News
Doctors are increasingly encouraged to factor costs into their drug prescribing decisions but very few clinical trials actually detail these costs, a Canadian study has found.
Clinical News
Roche has unveiled plans this morning to cut costs in response to pricing pressures and recent pipeline failures
The chief executive of Elan, Kelly Martin, is once again under fire from a shareholder who has made accusations about lack of disclosure and conflicts of interest
Takeda Pharmaceutical Co has signed a deal to develop and sell Orexigen Therapeutic's investigational obesity drug Contrave
Over the last decade, the percentage of Americans taking at least one prescription drug in the past month rose 10%, while the use of multiple prescription drugs grew 20% and the use of five or more drugs rose 70%, says the federal government.
Pfizer has hit the acquisition trail again and is buying FoldRx Pharmaceuticals, in a move that will boost its presence in orphan and rare disease markets
AstraZeneca will be celebrating news that its antipsychotic Seroquel XR has been given the European Commission’s seal of approval as an add-on treatment for major depressive episodes in patients with Major Depressive Disorder (MDD).
UK drugmaker Archimedes Pharma will be corking the champagne after receiving a regulatory green light to market its flagship pain spray PecFent (formerly NasalFent) throughout the European Union.
Cancer Research UK has started clinical trials of Merck & Co’s MK-0752 in combination with Eli Lilly’s Gemzar in patients with advanced pancreatic cancer.
Giving GPs responsibility for commissioning alongside service provision is crucial for better integration of health services and thus overall outcomes, a report by The Nuffield Trust has concluded
Bristol-Myers Squibb/Pfizer’s apixaban can more than halve the risk of stroke or systemic embolism compared with aspirin in patients with atrial fibrillation who cannot take warfarin, the results of the AVERROES trial have shown.
Companies “have only scratched the surface” in their efforts to understand patient psychology so that clinical trial protocols can be better geared to meeting recruitment targets, say consultants Cutting Edge Information.
The Institute of Clinical Research in India (ICRI) has formed a strategic partnership with Accenture to develop an educational programme in clinical research and pharmacovigilance.
What is joint working? Find out more here
Find your next job
